Silence Therapeutics (SLN) Payables (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Payables data on file, last reported at $10.4 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 44.89% year-over-year to $10.4 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (down 44.89% YoY), and the FY2025 full-year result was $13.4 million, down 18.56% from the prior year.
• Payables retreated to $10.4 million in Q1 2026, from $13.4 million in the prior quarter.
• In the past five years, Payables ranged from a high of $18.8 million in Q1 2025 to a low of $10.4 million in Q1 2026.
• A 5-year average of $15.1 million and a median of $15.1 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables rose 6.31% in 2024 and plunged 44.89% in 2026, its largest moves.
• Tracing SLN's Payables over 5 years: stood at $14.8 million in 2022, then advanced by 4.11% to $15.4 million in 2023, then increased by 6.31% to $16.4 million in 2024, then decreased by 18.56% to $13.4 million in 2025, then fell by 22.38% to $10.4 million in 2026.
• Business Quant data shows SLN's Payables at $10.4 million in Q1 2026, $13.4 million in Q4 2025, and $17.0 million in Q3 2025.